Intellipharmaceutics
International Inc. (IPCI) is a pharmaceutical company that develops
and commercializes novel and generic controlled-release and
targeted-release oral solid dosage drugs. The company uses its
proprietary Hypermatrix technology to create controlled-release drug
delivery systems.
IPCI has a portfolio of generic drug
products, which includes both extended-release and immediate-release
versions of well-known branded drugs. In addition to its generic
portfolio, the company has a number of drug candidates in various
stages of development, including Rexista, a novel, abuse-deterrent
oxycodone formulation designed to discourage common methods of abuse.
The company's Hypermatrix technology is a platform for the
creation of controlled-release drug delivery systems, which are
designed to release drugs over a specific period of time. This
technology can be used to create a wide range of drug delivery
systems, including matrix tablets, capsules, and osmotic systems.
IPCI has partnerships with several pharmaceutical companies to
develop and commercialize its drug products. The company also has a
licensing agreement with Par Pharmaceutical, Inc. for the development
and commercialization of generic versions of certain drugs.
In
recent years, IPCI has faced some challenges related to the
commercialization of its drug products. In particular, the company has
faced delays and obstacles related to the approval and
commercialization of its Rexista drug candidate. However, the company
has continued to pursue the development and commercialization of its
drug products, and has expressed confidence in the potential of its
Hypermatrix technology platform.
Overall, IPCI is a
pharmaceutical company that is focused on the development and
commercialization of controlled-release and targeted-release oral
solid dosage drugs, using its proprietary Hypermatrix technology
platform. While the company has faced some challenges in recent years,
it continues to pursue the development and commercialization of its
dru
|
